Ceftolozane/tazobactam for difficult‐to‐treat Gram‐negative infections : A real‐world tertiary hospital experience
Abstract Objective To evaluate the real‐world clinical efficacy of ceftolozane/tazobactam (C/T) in difficult‐to‐treat infections caused by multi‐drug resistant Gram‐negative microorganisms, including carbapenem‐resistant Pseudomonas aeruginosa. Methods Retrospective cohort study of adult patients treated with C/T for at least 48 hours for infections caused by multi‐drug resistant Gram‐negative bacteria in a tertiary hospital from May 2016 until August 2019. The primary outcome analysed was clinical failure, defined as a composite of symptomatology persistence after 7 days of C/T treatment, infection recurrence, and/or all‐cause mortality within 30 days of follow‐up. Results and discussion96 episodes of C/T treatment were included, mostly consisting of targeted treatments (83.9%) for the following sources of infection: intra‐abdominal (22.6%), urinary tract (25.8%), skin and soft tissue (19.4%), hospital‐acquired pneumonia (14%), and other (6.4%). The most frequently isolated bacteria were carbapenem‐resistant (88, 94.6%). Clinical failure rate was 30.1%, due to persistent infection at day 7 (4.3%), recurrence of the initial infection (16.1%), or 30‐day all‐cause mortality (8.6%). Adverse events most frequently reported were Clostridium difficile infection (9%) and cholestasis (8%). What is new and conclusion C/T showed a favourable clinical profile for difficult‐to‐treat multidrug‐resistant and carbapenem‐resistant Gram‐negative infections, regardless of the source of infection..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Journal of clinical pharmacy and therapeutics - 47(2022), 7, Seite 932-939 |
| Beteiligte Personen: |
Ronda, Mar [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
Copyright © 2022 John Wiley & Sons Ltd |
|---|
| Umfang: |
8 |
|---|
| doi: |
10.1111/jcpt.13623 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY008068658 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY008068658 | ||
| 003 | DE-627 | ||
| 005 | 20230307174240.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230216s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/jcpt.13623 |2 doi | |
| 028 | 5 | 2 | |a JCPT_JCPT13623.xml |
| 035 | |a (DE-627)WLY008068658 | ||
| 035 | |a (WILEY)JCPT13623 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Ronda, Mar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ceftolozane/tazobactam for difficult‐to‐treat Gram‐negative infections |b A real‐world tertiary hospital experience |
| 264 | 1 | |c 2022 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Copyright © 2022 John Wiley & Sons Ltd | ||
| 520 | |a Abstract Objective To evaluate the real‐world clinical efficacy of ceftolozane/tazobactam (C/T) in difficult‐to‐treat infections caused by multi‐drug resistant Gram‐negative microorganisms, including carbapenem‐resistant Pseudomonas aeruginosa. Methods Retrospective cohort study of adult patients treated with C/T for at least 48 hours for infections caused by multi‐drug resistant Gram‐negative bacteria in a tertiary hospital from May 2016 until August 2019. The primary outcome analysed was clinical failure, defined as a composite of symptomatology persistence after 7 days of C/T treatment, infection recurrence, and/or all‐cause mortality within 30 days of follow‐up. Results and discussion96 episodes of C/T treatment were included, mostly consisting of targeted treatments (83.9%) for the following sources of infection: intra‐abdominal (22.6%), urinary tract (25.8%), skin and soft tissue (19.4%), hospital‐acquired pneumonia (14%), and other (6.4%). The most frequently isolated bacteria were carbapenem‐resistant (88, 94.6%). Clinical failure rate was 30.1%, due to persistent infection at day 7 (4.3%), recurrence of the initial infection (16.1%), or 30‐day all‐cause mortality (8.6%). Adverse events most frequently reported were Clostridium difficile infection (9%) and cholestasis (8%). What is new and conclusion C/T showed a favourable clinical profile for difficult‐to‐treat multidrug‐resistant and carbapenem‐resistant Gram‐negative infections, regardless of the source of infection. | ||
| 700 | 1 | |a Pérez‐Recio, Sandra |4 aut | |
| 700 | 1 | |a González Laguna, Mònica |4 aut | |
| 700 | 1 | |a Tubau Quintano, Maria de la Fe |4 aut | |
| 700 | 1 | |a Llop Talaveron, Josep |4 aut | |
| 700 | 1 | |a Soldevila‐Boixader, Laura |4 aut | |
| 700 | 1 | |a Carratalà, Jordi |4 aut | |
| 700 | 1 | |a Cuervo, Guillermo |4 aut | |
| 700 | 1 | |a Padullés, Ariadna |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical pharmacy and therapeutics |d Oxford [u.a.] : Wiley-Blackwell, 1987 |g 47(2022), 7, Seite 932-939 |w (DE-627)WLY008060959 |w (DE-600)2006678-8 |x 13652710 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2022 |g number:7 |g pages:932-939 |g extent:8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.40 |q ASE |
| 951 | |a AR | ||
| 952 | |d 47 |j 2022 |e 7 |h 932-939 |g 8 | ||